SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001683168-24-002033
Filing Date
2024-04-01
Accepted
2024-04-01 17:01:12
Documents
15
Period of Report
2024-04-01
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT cns_8k.htm   iXBRL 8-K 27976
2 PRESS RELEASE cns_ex9901.htm EX-99.1 21128
6 GRAPHIC image_001.jpg GRAPHIC 9054
  Complete submission text file 0001683168-24-002033.txt   243029

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE cnsp-20240401.xsd EX-101.SCH 3018
4 XBRL LABEL FILE cnsp-20240401_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE cnsp-20240401_pre.xml EX-101.PRE 22361
18 EXTRACTED XBRL INSTANCE DOCUMENT cns_8k_htm.xml XML 3802
Mailing Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027
Business Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027 1-800-946-9185
CNS Pharmaceuticals, Inc. (Filer) CIK: 0001729427 (see all company filings)

IRS No.: 822318545 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39126 | Film No.: 24810632
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)